Evidence map›Paper›PMID 40979604›Full record

ArticleSultan Qaboos University medical journal2025

High SPINK1 Immunostaining in Colorectal Carcinoma is Associated with Poor Outcomes.

Ola Nasser, Wafaey Gomaa, Wafaa Aref, Rabab Moussa

Abstract read
In one paragraph

Article in Sultan Qaboos University medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ola NasserDepartment of Pathology, Faculty of Medicine, Minia University, Al-Minia, Egypt.ORCID 0009-0005-8197-1283
Wafaey GomaaDepartment of Pathology, Faculty of Medicine, Minia University, Al-Minia, Egypt.ORCID 0000-0002-6282-1037
Wafaa ArefDepartment of Pathology, Faculty of Medicine, Minia University, Al-Minia, Egypt.
Rabab MoussaDepartment of Pathology, Faculty of Medicine, Minia University, Al-Minia, Egypt.ORCID 0000-0003-3212-4131

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Colorectal cancer (CRC) is the third most common cancer worldwide and is the second leading cause of cancer-related deaths. Serine protease inhibitor Kazal-type 1 (SPINK1) is found to be related to poor prognostic criteria and shortened overall survival of some malignancies such as liver, breast, lung, pancreatic and renal cancers. SPINK1 can be a potential biomarker for early detection and prediction of immune checkpoint blockade treatment response. Therefore, this study aimed to examine the possible role of SPINK1 in colorectal carcinogenesis and its prognostic ability. Methods: This study used paraffin blocks of patients diagnosed with colorectal adenoma, primary CRC and available positive lymph node metastases. Specimens were obtained between April 2018 and June 2022 at the Department of Pathology, Faculty of Medicine, Minia University, Egypt. Immunohistochemistry was done for SPINK1 antibody and appropriate statistical analysis of results was performed. Results: A total of 70 archival samples of CRC, 18 of colorectal adenoma and 20 of metastatic lymph nodes were used in this study. In a normal colon, there was a negative to weak SPINK1 immunostaining. High cytoplasmic immunostaining was seen in 57.1% of patients while low immunostaining in 42.9% of CRC. SPINK1 immunostaining was statistically associated with tumour grade ( Conclusion: SPINK1 immunostaining is increased in CRC and associated with poor prognostic criteria and is significantly associated with immunoactivity in adenoma and associated nodal metastasis.

Indexed as

Colorectal NeoplasmsTrypsin Inhibitor, Kazal PancreaticAdultAgedBiomarkers, TumorEgyptFemaleHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedPrognosisBiomarkers, TumorSPINK1 protein, humanTrypsin Inhibitor, Kazal PancreaticColorectal CancerEgyptImmunohistochemistryPrognosisSPINK1

Identifiers

PMID40979604
PMCPMC12445310

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.